Hubbard U and Hund's Exchange J in Transition Metal Oxides: Screening vs. Localization Trends from Constrained Random Phase Approximation

In this work, we address the question of calculating the local effective Coulomb interaction matrix in materials with strong electronic Coulomb interactions from first principles. To this purpose, we implement the constrained random phase approximation (cRPA) into a density functional code within the linearized augmented plane wave (LAPW) framework. We apply our approach to the 3d and 4d early transition metal oxides SrMO3 (M=V, Cr, Mn) and (M=Nb, Mo, Tc) in their paramagnetic phases. For these systems, we explicitly assess the differences between two physically motivated low-energy Hamiltonians: The first is the three-orbital model comprising the t2g states only, that is often used for early transition metal oxides. The second choice is a model where both, metal d- and oxygen p-states are retained in the construction of Wannier functions, but the Hubbard interactions are applied to the d-states only ("d-dp Hamiltonian"). Interestingly, since -- for a given compound -- both U and J depend on the choice of the model, so do their trends within a family of these compounds. In the 3d perovskite series SrMO3 the effective Coulomb interactions in the t2g Hamiltonian decrease along the series, due to the more efficient screening. The inverse -- generally expected -- trend, increasing interactions with increasing atomic number, is however recovered within the more localized "d-dp Hamiltonian". Similar conclusions are established in the layered 4d perovskites series Sr2MO4 (M=Mo, Tc, Ru, Rh). Compared to their isoelectronic and isostructural 3d analogues, the 4d 113 perovskite oxides SrMO3 (M=Nb, Mo, Tc) exhibit weaker screening effects. Interestingly, this leads to an effectively larger U on 4d shells than on 3d when a t2g model is constructed.Comment: 21 pages, 7 figure

« New Modalities in Cancer Imaging and Therapy » XVe édition de l’atelier organisé par le réseau « Vectorisation, Imagerie, Radiothérapies » du Cancéropôle Grand-Ouest, 5–8 octobre 2022, Erquy, France

National audienceThe fifteenth edition of the international workshop organized by the "Tumour Targeting and Radiotherapies network" of the Cancéropôle Grand-Ouest focused on the latest advances in internal and external radiotherapy from different disciplinary angles: chemistry, biology, physics, and medicine. The workshop covered several deliberately diverse topics: the role of artificial intelligence, new tools for imaging and external radiotherapy, theranostic aspects, molecules and contrast agents, vectors for innovative combined therapies, and the use of alpha particles in therapy

Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer

International audienceBackground: Stereotactic body radiotherapy (SBRT) is a recognized treatment for colorectal cancer (CRC) metastases. We postulated that local responses could be improved by SBRT with a concomitant radiosensitizing agent (irinotecan). Methods: RADIOSTEREO-CAMPTO was a prospective multi-center phase 2 trial investigating SBRT (40–48 Gy in 4 fractions) for liver and/or lung inoperable CRC oligometastases (3), combined with two weekly intravenous infusions of 40 mg/m2 Irinotecan. Primary outcome was the objective local response rate as per RECIST. Secondary outcomes were early and late toxicities, EORTC QLQ-C30 quality of life, local control and overall survival. Results: Forty-four patients with 51 lesions (liver = 39, lungs = 12) were included. Median age was 69 years (46–84); 37 patients (84%) had received at least two prior chemotherapy treatments. Median follow-up was 48.9 months. One patient with two lung lesions was lost during follow-up. Assuming maximum bias hypothesis, the objective local response rate in ITT was 86.3% (44/51—95% CI: [76.8–95.7]) or82.4% (42/51—95% CI: [71.9–92.8]). The observed local response rate was 85.7% (42/49—95% CI: [75.9–95.5]). The 1 and 2-year local (distant) progression-free survivals were 84.2% (38.4%) and 67.4% (21.3%), respectively. The 1 and 2-year overall survivals were 97.5% and 75.5%. There were no severe acute or late reactions. The EORTC questionnaire scores did not significantly worsen during or after treatment. Conclusions: SBRT with irinotecan was well tolerated with promising results despite heavily pretreated patients